Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Rating) had its price target lifted by analysts at Morgan Stanley from €77.00 ($82.80) to €83.00 ($89.25) in a research report issued on Monday, The Fly reports. The brokerage currently has an “overweight” rating on the stock.
A number of other analysts also recently issued reports on the company. Jefferies Financial Group initiated coverage on Bayer Aktiengesellschaft in a report on Monday, March 14th. They set a “buy” rating for the company. Citigroup raised Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, January 31st. UBS Group lifted their price target on Bayer Aktiengesellschaft from €85.00 ($91.40) to €90.00 ($96.77) in a report on Friday, March 11th. Finally, Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, April 5th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $61.20.
Shares of BAYRY traded down $0.03 during midday trading on Monday, hitting $17.92. 601,500 shares of the stock were exchanged, compared to its average volume of 605,100. Bayer Aktiengesellschaft has a 52-week low of $12.45 and a 52-week high of $18.45. The stock has a fifty day simple moving average of $16.29 and a 200 day simple moving average of $14.80. The firm has a market cap of $70.42 billion, a P/E ratio of 61.80, a P/E/G ratio of 2.43 and a beta of 1.17. The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.72 and a current ratio of 1.11.
About Bayer Aktiengesellschaft (Get Rating)
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
- Get a free copy of the StockNews.com research report on Bayer Aktiengesellschaft (BAYRY)
- Hasbro Insider Bets Big On Stock Rebound
- The Coca-Cola Company Gets KO’d After Stunning Quarter
- Schwab Stock Can Be Caught Down Here
- Snap Up Some Snap-On On Post-Earnings Weakness
- Time to Buy any Dip in Prologis Stock
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.